BofA lowered the firm’s price target on GoodRx (GDRX) to $4.25 from $4.50 and keeps an Underperform rating on the shares after the company announced the resignation of CFO Karsten Voermann. The outlook for GoodRx’s core prescription business is unclear heading into 2025, as pharmacies are pushing back more aggressively on pharmacy benefit manager reimbursements which could cause PBM economics to come under some pressure, the analyst tells investors in a research note. The firm added that it remains cautious on the growth trajectory in 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue